+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Circulating Tumor Cell (CTC) Diagnostics: Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 2832326

Global Circulating Tumor Cell (CTC) Diagnostics Market to Reach $21.3 Billion by 2030

The global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$9.1 Billion in the year 2022, is projected to reach a revised size of US$21.3 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2022-2030. Detection & Enrichment, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$13.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Analysis segment is readjusted to a revised 12.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.7 Billion, While China is Forecast to Grow at 10.3% CAGR

The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 9.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Select Competitors (Total 48 Featured) -

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Market Outlook
  • Recent Market Activity
  • Clinical Relevance of CTCs
  • CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy
  • Major Challenges in CTC Diagnostics
  • Need for CTC Enrichment and Popular Methods
  • CTC Enrichment Techniques
  • Select Available CTC Detection Technologies
  • Select CTC Isolation Systems - A Brief Comparison
  • CTC Identification - Various Approaches
  • CTC Identification Approaches
  • List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type
  • CellSearch System™ - The First FDA Approved Automated Enrichment/Isolation Technique
  • Rising Incidence of Cancer - An Opportunity Indicator
  • Cancer Prone Sites based on Age
  • Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • ApoCell, Inc. (US)
  • Biocep Ltd. (Israel)
  • Biocept, Inc. (US)
  • Biofluidica Microtechnologies LLC (US)
  • Celltraffix Inc. (US)
  • Clearbridge Biomedics (Singapore)
  • Creatv Microtech, Inc. (US)
  • Cynvenio Biosystems, Inc. (US)
  • Epic Biosciences Inc. (US)
  • Fluxion Biosciences, Inc. (US)
  • Ikonisys, Inc. (US)
  • IVDiagnostics, Inc. (US)
  • Janssen Diagnostics LLC (US)
  • QIAGEN Hannover GmbH (Germany)
  • RARECELLS SAS (Italy)
  • ScreenCell (France)
  • STEMCELL Technologies, Inc. (Canada)
3. MARKET TRENDS & DRIVERS
  • Liquid Biopsy - the New Buzzword in Healthcare
  • Select Companies Active in Cancer Liquid Biopsy
  • CTCs for Personalized Cancer Treatment
  • Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis
  • CTC Microdevices Hog the Limelight
  • Increasing Research Reveal Further Complexities to CTC Composition and Behavior
  • EpCAM Glycoprotein - Insufficient for CTC Detection
  • New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs
  • Physical Property-based Enrichment Technologies Lose Fizz
  • Evidence in Favor CTC Heterogeneity Gains Strength
  • CTC Clusters Raise Research Interest
  • Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings
  • Limitations of CTC Technology for Point-of-Care Testing
  • CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
  • Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?
  • Select Research Findings in Recent Years
  • Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
  • NBiomics Makes its Contribution to CTC Diagnosis
  • Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
  • Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
  • Gold Nanoparticles Help in the Detection of CTCs
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Detection & Enrichment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Direct Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 18: World 18-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 21: World 18-Year Perspective for Other Body Fluids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 24: World 18-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 27: World 18-Year Perspective for Clinical / Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 28: World Circulating Tumor Cell (CTC) Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
CANADA
JAPAN
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
CHINA
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
EUROPE
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
FRANCE
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
GERMANY
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
ITALY
UNITED KINGDOM
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

Table Information